Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bicara Therapeutics Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-09 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-09
Exact text from the filing
Proposal 2: Ratification of KPMG LLP The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows: Votes For Votes Against Votes Abstaining Ratification of appointment of KPMG LLP 55,914,602 8,815 1,570
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bicara Therapeutics Inc. shareholders approved Election of Class II Directors at the 2026-06-09 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-09
Exact text from the filing
Proposal 1: Election of Directors The Company's stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows: Director Votes For Votes Withheld Broker Non-Votes Christopher Bowden, M.D. 48,558,710 5,145,418 2,220,859 Carolyn Ng, Ph.D. 47,431,269 6,272,859 2,220,859
View on SEC.gov